Roche has stopped a Phase 3 trial of aleglitazar for patients with Type 2 diabetes who are at risk of cardiovascular disease because of adverse events and a lack of efficacy. This follows a review by an independent data and safety monitoring board. ---Subscribe to MedNous to access this article--- Clinical Research Company News